Am I experiencing a relapse? Format your response so a patient skimming on their phone gets the point first. Begin...

TL;DR: Your bone marrow biopsy results on 6/1/26 will tell you and your doctor whether you're experiencing a relapse—high blast cells and abnormal CD34 donor cells are concerning signs, but only your oncologist can interpret your complete clinical picture to make this determination.

---

KEY POINTS:

• High blast cells in your blood are a red flag that needs urgent evaluation by your transplant team
• Your CD34 donor cells at 0% is abnormal and suggests your donor bone marrow may not be engrafting properly
• The timing matters: Your 6/9/26 follow-up is critical—bring your biopsy results and ask directly about relapse risk
• DLI (donor lymphocyte infusion) cells are different from cells given at transplant and are used as a treatment strategy, not a diagnostic tool
• Your symptoms (high blasts, high eosinophils, low lymphocytes) need context from your pathology report to interpret

NEXT STEP: At your 6/9/26 appointment, ask your oncologist directly: "Based on my bone marrow biopsy, am I experiencing a relapse, and what do my blast cell counts and CD34 results mean for my treatment plan?"

---

FULL ANSWER

Understanding Your Situation

I want to be direct with you: I cannot tell you whether you're experiencing a relapse. Only your transplant oncologist can make that determination by looking at your complete clinical picture—your bone marrow biopsy pathology, your blood counts, your imaging, and your medical history together.

However, I can help you understand what your doctors are likely evaluating:

---

What Your Symptoms and Biomarkers Suggest

High Blast Cells = Urgent Signal

Blast cells are immature blood cells. When they're elevated in your blood or bone marrow after an allogeneic hematopoietic stem cell transplant (allo-HSCT), this is a concerning sign that needs immediate investigation. High blasts can indicate:

• Disease relapse (your original cancer returning)
• Graft failure (your donor cells not engrafting properly)
• Secondary malignancy (a new blood cancer developing post-transplant)
• Other post-transplant complications

Your bone marrow biopsy on 6/1/26 was the right test to investigate this. The pathology report will show:

• The percentage of blasts in your marrow
• Their morphology (what they look like under the microscope)
• Whether they match your original disease or represent something new

Your CD34 Donor Cells at 0% = Abnormal Engraftment

CD34 is a marker for hematopoietic stem cells (blood-forming cells). Your test shows:

• 0% donor CD34 cells = Your donor's stem cells are not present in your bone marrow
• This is abnormal and suggests graft failure or graft loss

This is different from relapse but is equally serious. It means your bone marrow may not be producing healthy blood cells from the donor source, which can lead to:

• Cytopenias (low blood counts)
• Increased infection risk
• Potential disease recurrence (because you've lost the graft-versus-leukemia effect)

Your Other Biomarkers (CD19, CD15, CD3)

These markers track different immune cell populations. Without seeing your actual values and percentages, I can't interpret them specifically, but your transplant team is using them to assess:

• Whether donor immune cells are present
• Whether your immune system is recovering
• Whether there's evidence of graft-versus-host disease (GVHD)

Your Symptoms in Context

• High eosinophils can suggest GVHD, infection, or leukemia
• Low lymphocytes suggest immune suppression or graft failure
• Together with high blasts, these paint a picture that needs urgent clarification

---

About DLI (Donor Lymphocyte Infusion) Cells

To answer your specific question: DLI cells are NOT the same as cells infused at transplant.

At transplant (allo-HSCT):

• You receive the entire donor graft: stem cells, T cells, B cells, and other immune cells
• This is a mixed population designed to rebuild your entire immune system

DLI (Donor Lymphocyte Infusion):

• Contains primarily T lymphocytes (immune cells) from the same donor
• Given after transplant as a treatment strategy
• Used to boost the graft-versus-leukemia (GVL) effect if relapse is detected
• Can help control disease but carries risk of GVHD

DLI is a treatment option, not a diagnostic test. It won't tell you if you're in relapse—your biopsy will.

---

How Doctors Determine Relapse After Allo-HSCT

According to NCCN Guidelines for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), relapse after transplant is diagnosed by:

1. Morphologic relapse: ≥5% blasts in bone marrow or blood (or extramedullary disease)
2. Cytogenetic/molecular relapse: Return of original cytogenetic or molecular abnormalities
3. Flow cytometry: Abnormal blast populations matching your original disease

Your bone marrow biopsy will provide this information. Your pathologist will:

• Count the percentage of blasts
• Characterize their immunophenotype (what markers they express)
• Compare them to your original disease characteristics
• Look for cytogenetic abnormalities

---

Why Your 6/9/26 Appointment Is Critical

Your follow-up in just over a week is not routine—it's urgent. Your transplant team needs to:

1. Review your biopsy results in detail
2. Assess your current blood counts (CBC with differential)
3. Determine the cause of your high blasts (relapse vs. graft failure vs. other)
4. Decide on next steps (which may include DLI, chemotherapy, clinical trials, or other interventions)

---

Questions to Ask Your Doctor on 6/9/26

Come prepared with these specific questions:

1. "What percentage of blasts did the pathologist find in my bone marrow biopsy, and what does that mean?"
2. "Do my blast cells match my original disease, or are they something new?"
3. "What do my CD34 results mean—am I experiencing graft failure?"
4. "Based on all my results, am I in relapse, and if so, what stage?"
5. "What are my treatment options, and how urgent is it to start treatment?"
6. "Would I be a candidate for DLI, a clinical trial, or other therapies?"

---

What the Evidence Says

According to NCCN Guidelines for Hematopoietic Cell Transplantation and ASCO Guidelines on Post-Transplant Monitoring:

• Patients with high blast counts post-transplant require urgent evaluation to distinguish relapse from other complications
• Early detection and treatment of post-transplant relapse improves outcomes
• Treatment options depend on the specific diagnosis and may include DLI, chemotherapy, targeted therapy, or clinical trials
• Graft failure (which your CD34 results suggest) is a medical emergency requiring intervention

---

The Bottom Line

You cannot know if you're in relapse without your biopsy results and your doctor's interpretation. What I can tell you is:

• Your symptoms and biomarkers are concerning enough that your transplant team ordered urgent testing
• Your biopsy results will provide the answer
• Your 6/9/26 appointment is not optional—it's critical
• Treatment decisions depend on the diagnosis, so getting clarity quickly matters

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Your transplant oncologist has access to your complete [ID removed] imaging, and pathology—they are the only one who can answer whether you're experiencing a relapse. Come to your appointment with your questions written down, bring someone to take notes if possible, and ask for a clear explanation of your biopsy results.

You're asking the right questions. Keep advocating for yourself.